Catalog No.
Product Name
Application
Product Information
Citations
-
Factor Xa inhibitor
Apixaban is an anticoagulant for the prevention of venous thromboembolism and venous thromboembolic events.- Daniël Verhoef, .et al. , Nat Commun, 2017, 8: 528 PMID: 28904343
-
Factor Xa inhibitor
BMS-740808 is a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
-
Factor Xa inhibitor
Rivaroxaban is an oxazolidinone derivative optimized for inhibiting both free Factor Xa and Factor Xa bound in the prothrombinase complex.- Stefan Bittmann, .et al. , J Regen Biol Med, 2020, 2(2):1-3
- Daniël Verhoef, .et al. , Nat Commun, 2017, 8: 528 PMID: 28904343
- Mizuki Yamamoto, .et al. , Antimicrob Agents Chemother, 2016, Nov; 60(11): 6532-6539 PMID: 27550352
-
factor Xa inhibitor
Otamixaban(FXV 673) is an intravenous direct factor Xa inhibitor.- Tim Hempel, .et al. , Chemical Science, 2021, 12, 12600-12609
-
thrombin/factor Xa dual inhibitor
RWJ-445167 (3DP-10017) is a dual inhibitor of thrombin and factor Xa with Ki of 4.0 nM and 230 nM, respectively, exhibiting potent antithrombotic activity. - Rivaroxaban is an oxazolidinone derivative optimized for inhibiting both free Factor Xa and Factor Xa bound in the prothrombinase complex.
-
FXa Inhibitor
Betrixaban is an anticoagulant drug which acts as a direct factor Xa inhibitor. It is potent, orally active and highly selective for factor Xa, being selected from a group of similar compounds for its low hERG affinity. -
factor Xa inhibitor
Letaxaban, also known as TAK-442, is a potent, selective, and orally active factor Xa inhibitor, which is a tetrahydropyrimidin-2(1H)-one derivative. TAK-442 inhibited endogenous FXa activity in platelet-poor human [half-maximal inhibitory concentration (IC(50)): 53 nM, TAK-442] and rat (IC(50): 32 nM, TAK-442) plasma. -
Factor Xa inhibitor
Edoxaban is a selective factor Xa inhibitor with Ki of 0.561 nM- Daniël Verhoef, .et al. , Nat Commun, 2017, 8: 528 PMID: 28904343
-
Factor Xa inhibitor
5-R-Rivaroxaban is (R) enantiomer of Rivaroxaban. Rivaroxaban is a novel, oral, direct Factor Xa (FXa) inhibitor in late-stage development for the prevention and treatment of thromboembolic disorders. -
Factor Xa inhibitor
Edoxaban is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention. -
factor Xa inhibitor
Fondaparinux sodium is a factor Xa inhibitor to form the high affinity binding site for the anti-coagulant factor antithrombin III (ATIII). -
FXIa inhibitor
BMS-962212 is a reversible, direct, and highly selective inhibitor of FXIa. -
Factor XIa (FXIa) inhibitor
BMS-654457 is a small-molecule, reversible inhibitor of factor XIa (FXIa), binding with human and rabbit FXIa with Kis of 0.2 and 0.42 nM, respectively. -
Factor Xa Inhibitor
ChloraMine-T hydrate is a selective Factor Xa inhibitor known for its utility in synthetic chemistry. It serves as a versatile reagent in aminohydroxylation and allylic amination reactions, functioning as a nitrogen source in the aziridination of alkenes and facilitating the deprotection of sulfur groups in thiol-containing compounds. Additionally, ChloraMine-T hydrate exhibits antimicrobial properties, demonstrating efficacy against various bacterial strains, including Staphylococcus epidermidis, Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Proteus mirabilis, and Enterococcus cloacae, making it valuable for applications in both enzymatic inhibition studies and antimicrobial research. -
Factor Xa Inhibitor
DPC423 free base is a selectively potent Factor Xa inhibitor, demonstrating inhibition constants (Kis) of 0.15 nM in humans and 0.3 nM in rabbits. It exhibits moderate selectivity with Kis of 60 nM against human trypsin, 61 nM against plasma kallikrein, and 6000 nM against thrombin. By inhibiting the formation of the prothrombinase complex, DPC423 reduces thrombin generation, thereby obstructing fibrin formation and platelet activation. This compound is valuable for research applications related to anticoagulation in arterial thrombosis. -
Factor Xa Substrate
CH3OCO-D-CHA-Gly-Arg-pNA acetate is a chromogenic substrate specifically designed for the enzymatic activity of Factor Xa. Upon cleavage by Factor Xa, it releases p-nitroaniline, which can be quantitatively measured to assess enzymatic function. This compound is valuable for studies involving coagulation cascades and is commonly used in research applications focused on thrombosis and hemostasis. -
Factor Xa
Bovine Factor Xa is a trypsin-like serine protease that plays a critical role in the coagulation cascade, facilitating thrombin generation. This enzyme is commonly used in research applications related to blood coagulation, hemostasis, and thrombolysis. Its ability to activate prothrombin into thrombin makes it valuable for studies aiming to understand clot formation and regulation. -
Thrombin/ Factor Xa Inhibitor
Ciraparantag is a potent inhibitor of thrombin and factor Xa, serving as a broad-spectrum reversal agent for various anticoagulants. This compound effectively neutralizes the effects of low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants, while sparing vitamin K antagonists and argatroban. Its unique mechanism makes Ciraparantag a valuable tool for research focused on anticoagulation reversal and hemostasis. -
Factor Xa Inhibitor
Dechloro Rivaroxaban is a potent, selective inhibitor targeting Factor Xa, demonstrating a Ki of 0.4 nM against human free FXa. This compound effectively inhibits prothrombinase activity and fibrin-associated FXa activity, exhibiting IC50 values of 2.1 nM and 92 nM, respectively. Dechloro Rivaroxaban is suitable for research applications focused on coagulation and antithrombotic drug development. -
Thrombin/Factor Xa Inhibitor
Ciraparantag acetate is a potent inhibitor of thrombin and factor Xa, serving as a broad-spectrum reversal agent for various anticoagulants, including low molecular weight heparins, unfractionated heparins, and certain direct oral anticoagulants, excluding vitamin K antagonists (VKAs). Its primary mechanism targets the coagulation pathway, facilitating the restoration of normal hemostasis in clinical situations where anticoagulation reversal is necessary. Ciraparantag acetate is valuable in research applications focused on anticoagulation management and hemostatic balance in cardiovascular studies. -
Factor Xa Inhibitor
Edoxaban impurity 6 is a chemical impurity associated with Edoxaban, a selective and potent oral inhibitor of factor Xa (FXa). It exhibits binding affinities with Kis of 0.561 nM for free FXa and 2.98 nM for prothrombinase, highlighting its significant role in anticoagulation. Research applications include studying the pharmacokinetics and safety profiles of FXa inhibitors, particularly in the context of stroke prevention and thromboembolic disorders. -
Factor Xa Inhibitor
Fidexaban is a potent Factor Xa inhibitor that plays a significant role in the modulation of the coagulation cascade. It is primarily utilized in cardiovascular disease research, providing valuable insights into thrombotic disorders and potential therapeutic strategies. Its mechanism of action contributes to the understanding of anticoagulant therapies and their implications in various pathological conditions. -
Factor Xa Inhibitor
FXIa-IN-7 is a selective, orally bioavailable inhibitor of Factor XIa, exhibiting an impressive IC50 value of 0.4 nM. This compound demonstrates potent antithrombotic potential, making it a valuable tool for research in coagulation pathways and thrombotic disorders. Its specificity towards Factor XIa positions FXIa-IN-7 as an important reagent for studies aimed at understanding the role of the intrinsic pathway in hemostasis and thrombosis. -
Factor Xa Inhibitor
Betrixaban hydrochloride is a highly potent and selective inhibitor of factor Xa (fXa), exhibiting an IC50 of 1.5 nM. This compound demonstrates significant antithrombotic activity, making it valuable for research applications focused on thrombosis and coagulation disorders. Betrixaban hydrochloride is suitable for studies investigating novel anticoagulant therapies and the mechanistic pathways of blood clotting. -
Factor Xa Inhibitor
Razaxaban hydrochloride is a selective and potent inhibitor of factor Xa, exhibiting a Ki of 0.19 nM. With over 5000-fold selectivity for factor Xa compared to other serine proteases, this compound effectively impedes the coagulation cascade. Additionally, Razaxaban hydrochloride displays thrombin inhibition with a Ki value of 540 nM, underscoring its significant antithrombotic properties. It is a valuable tool for research into anticoagulation therapies and the modulation of thrombotic disorders. -
Factor Xa Inhibitor
EMD 495235 is a potent and orally active inhibitor of coagulation factor Xa, exhibiting an IC50 of 5.5 nM and a Ki of 6.8 nM. This compound demonstrates significant anticoagulant activity, making it a valuable tool for research applications focused on thrombosis and hemostasis. EMD 495235 can be utilized to investigate the mechanisms of coagulation and evaluate potential therapeutic strategies for related disorders. -
Factor Xa Inhibitor
FXIa-IN-6 is a highly selective inhibitor of Factor XIa, demonstrating a Ki value of 0.3 nM. This compound is integral in studying the coagulation cascade and serves as a valuable tool in thrombosis research. Its ability to specifically target Factor XIa provides insights into potential therapies for clotting disorders while minimizing cross-reactivity with other serine proteases. -
Factor Xa Inhibitor
FXIa-IN-13 is a selective inhibitor of Factor Xa, displaying significant antithrombotic activity. This compound effectively inhibits arteriovenous thrombosis in both in vivo and in vitro models, making it a valuable tool for research on thrombosis and coagulation disorders. Its application in studying the mechanisms of blood clotting can provide insights into therapeutic strategies for cardiovascular diseases. -
Factor Xa Inhibitor
EMD-503982 is an orally bioavailable inhibitor of Factor Xa, a key enzyme in the coagulation cascade. By selectively inhibiting Factor Xa, this compound effectively reduces thrombin generation, making it a valuable tool in research focused on thrombosis and coagulation disorders. Its utility in various biological assays and preclinical studies further supports investigations into anticoagulant therapies and related cardiovascular research. -
Coagulation Factor Xa Inhibitor
L-Guluronic acid is a coagulation Factor Xa inhibitor that retains the inhibitory activity against Factor Xa while serving as a substitute for L-Iduronic acid in anticoagulant pentasaccharides derived from heparin-like substances. Its capacity to modulate coagulation processes makes it valuable in research focused on coagulation disorders, including deep vein thrombosis and pulmonary embolism. This compound facilitates the exploration of therapeutic strategies aimed at managing these significant vascular conditions. -
Factor Xa Inhibitor
RPR 130737 is a selective and potent competitive inhibitor of Factor Xa, exhibiting an inhibition constant (Ki) of 2.4 nM. This compound demonstrates over 1000-fold selectivity against thrombin, activated protein C, plasmin, tissue-plasminogen activator, and trypsin, making it an ideal tool for cardiovascular research. RPR 130737 effectively prolongs both activated partial thromboplastin time and prothrombin time while having no impact on platelet aggregation. It is primarily utilized in studies relating to thrombotic disorders and cardiovascular diseases. -
Factor Xa Inhibitor
RPR-208707 is a selective inhibitor of Factor Xa, exhibiting a Ki of 18 nM. This compound demonstrates significant anti-thrombotic activity, making it a valuable tool for research focused on thrombosis-related diseases. Its specificity for Factor Xa positions it as a potent candidate for exploring mechanisms of coagulation and potential therapeutic interventions in thrombotic disorders. -
Thrombin/Factor Xa Inhibitor
Ciraparantag TFA is a potent thrombin and factor Xa inhibitor utilized as a broad-spectrum reversal agent for anticoagulants. It effectively antagonizes the effects of various anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and specific direct oral anticoagulants, while sparing vitamin K antagonists and argatroban. This compound is significant for research applications focused on enhancing hemostatic management in patients receiving anticoagulant therapy. -
Thrombin/Factor Xa/Trypsin/Papain Inhibitor
Bacithrocin D is a potent inhibitor of key proteases, specifically targeting thrombin, factor Xa, trypsin, and papain. It effectively prolongs clotting time, making it valuable in studies related to coagulation and hemostasis. Bacithrocin D demonstrates IC50 values of 124 μM for thrombin, 9 μM for factor Xa, 0.85 μM for trypsin, and a remarkable 0.01 μM for papain, showcasing its high potency against these proteases. This reagent is useful for investigating protease-related pathways and developing therapeutic strategies in anticoagulation research. -
Factor Xa Inhibitor
(1R,2R,4R)-Edoxaban is a selective inhibitor of activated coagulation factor X (Factor Xa). It demonstrates potent anticoagulant activity, making it a valuable tool in the study of thrombosis and related cardiovascular conditions. This reagent is suitable for researching mechanisms of coagulation and evaluating therapies aimed at managing thromboembolic disorders. -
Factor Xa Inhibitor
BI-11634 is a potent factor Xa inhibitor that plays a critical role in anticoagulant research. It is primarily metabolized by the enzyme CYP3A4, leading to the formation of a major metabolite. The metabolism of BI-11634 can be inhibited by Quinidine, demonstrating a Ki value of 7 µM, indicating its potential importance in studies related to drug interactions and cardiovascular therapeutics. -
Factor Xa Inhibitor
Darexaban glucuronide is an active metabolite of darexaban, functioning as a potent inhibitor of Factor Xa. This compound exhibits significant oral bioactivity and demonstrates antithrombotic effects, making it valuable for research into thromboembolic disorders. Its properties support studies focused on anticoagulant therapies and the mechanistic understanding of coagulation pathways. -
Factor Xa Inhibitor
AS1468240 is a potent, orally active inhibitor of factor Xa (fXa), demonstrating an IC50 of 8.7 nM against human fXa. This compound effectively prolongs coagulation time in murine models, highlighting its potential as an anticoagulant agent. It serves as a valuable tool for research into coagulation pathways and the development of therapeutic strategies for thromboembolic disorders. -
Factor Xa Inhibitor
Tanogitran is a dual inhibitor that targets Factor Xa and thrombin, exhibiting Ki values of 26 nM and 2.7 nM, respectively. This compound demonstrates significant anticoagulant activity, making it valuable for research in thrombotic diseases and related cardiovascular studies. Researchers can utilize Tanogitran to investigate the mechanisms of coagulation and the potential therapeutic applications in anticoagulation therapy.
